Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the transitionExperienced life science executive David Szekeres appointed as PresidentKleanthis G. Xanthopoulos, Ph.D.

行业领袖巴里·夸特（Barry Quart，Pharm.D.）被任命为首席执行官，接替郑伟（Zheng Wei，Ph.D.），郑伟（Zheng Wei）将继续担任董事会成员，并担任顾问，协助过渡经验丰富的生命科学执行官大卫·塞克雷斯（DavidSzekeres）被任命为总裁克莱恩特（Kleanthis G.Xanthopoulos，Ph.D.）。

appointed as Chair of the Board of Directors SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today the appointments of Barry Quart, Pharm.D., as Chief Executive Officer (CEO) and Director, David Szekeres as President, and Kleanthis G.

2024年6月12日，被任命为美国加利福尼亚州圣地亚哥和中国太仓董事会主席（环球通讯社）--Connect Biopharma Holdings Limited（纳斯达克：CNTB）（Connect或该公司），一家总部位于美国的全球临床阶段生物制药公司，致力于通过开发源自T细胞驱动的研究的疗法来改善慢性炎症性疾病患者的生活，今天宣布任命Barry Quart Pharm.D.为首席执行官（CEO）和董事，David Szekeres为总裁，Kleanthis G。

Xanthopoulos, Ph.D., as the new Chair of the Board of Directors (Board). Dr. Xanthopoulos, currently the lead independent member of the Board since 2022, has been appointed Chair of the Board. Dr. Xanthopoulos succeeds Wubin (Bill) Pan, Ph.D., M.B.A., who will remain on the Board and serve as an advisor to the Company during the transition.

Xanthopoulos博士担任董事会（Board）新任主席。Xanthopoulos博士自2022年起担任董事会首席独立成员，已被任命为董事会主席。Xanthopoulos博士接替Wubin（Bill）Pan博士，工商管理硕士，他将继续留在董事会，并在过渡期间担任公司顾问。

“On behalf of the board and the Connect team I would like to thank Drs. Zheng Wei and Wubin (Bill) Pan, who co-founded Connect with the vision to bring next-generation therapeutics to patients with inflammatory diseases and improve their lives. We are grateful for their contributions and unwavering commitment to the Connect mission by building an outstanding organization with Phase 3-ready programs and a robust pipeline,” said Kleanthis G.

“我代表董事会和Connect团队感谢郑伟博士和潘武斌博士，他们共同创立了Connect with the vision，为炎症性疾病患者带来下一代治疗方法并改善他们的生活。我们感谢他们的贡献和对Connect使命的坚定承诺，通过建立一个具有3期就绪计划和强大渠道的优秀组织，”Kleanthis G。

Xanthopoulos, Ph.D., Chair of the Board of Directors of Connect. “The highly differentiated data generated from positive readouts in both asth.

Connect董事会主席Xanthopoulos博士。“两个哮喘患者的阳性读数产生了高度分化的数据。